Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 71 - 80 of 243
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: GeSea Biosciences, FHI 360, pH Sciences
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Epididymal Peptidase Inhibitor
Target
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Mithra
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Hera Health Solutions
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Gold T IUD; Novaplus T 380 Ag IUD; Novaplus T 380 Cu IUD; Ancora 375 Ag IUD; Ancora 375 Cu IUD; Ancora 250 Cu Mini IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Eurogine
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs
User: Female
Hormonal: Yes
Developer: Evestra, Inc.
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Etonogestrel (ENG) + Ethinyl Estradiol (EE) Vaginal Ring; EVE112
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Evestra, Inc., Gedeon Richter Plc.
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Evestra, Inc.
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Famy Care Ltd.
Development Stage: Marketed
Development Phase: Limited Market Availability

Pages

Displaying 21 - 30 of 70
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: National Research Institute for Family Planning in Beijing
Development Stage: Prototype Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Alternative Name: Inhibition of Vas Propulsive Contractility
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: King's College, London
Development Stage: Lead Optimization
Alternative Name: K4K20S4
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other, Other
Development Stage: Lead Optimization
Alternative Name: Plasma Membrane Calcium ATPase (PMCA) Inhibitors
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: University of Manchester, Max Planck Institute
Alternative Name: Electrospun fiber meshes
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Development Stage: Prototype Development
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Contraline, LLC
Development Stage: Lead Optimization
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Alternative Name: Epididymal Peptidase Inhibitor
Target
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Evestra, Inc.
Development Stage: Prototype Development

Pages

Displaying 71 - 80 of 121
Alternative Name: Nestorone (NES) Single Rod Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council
Development Stage: Phase II
Alternative Name: Nestorone + Testosterone Gel
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Development Stage: Phase II
Alternative Name: Nestorone (NES) Metered Dose Transdermal System® (MDTS®)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council, Acrux, Ltd., Fempharm Pty Ltd.
Development Stage: Phase I
Alternative Name: Nestorone (NES) + Estradiol (E2) Transdermal Gel
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Antares, Population Council
Development Stage: Phase II
Alternative Name: Biodegradable Norethindrone (NET) Pellets
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Anterion Therapeutics, FHI 360
Development Stage: Phase II
Alternative Name: Non-Invasive Laser Male Sterilization
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Vas Deferens
Developer: University of North Carolina at Charlotte
Development Stage: Pre-clinical
Alternative Name: Oil-based drospirenone (DSRP) microcrystal suspension
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Bayer HealthCare
Development Stage: Pre-clinical
User: Male
Hormonal: No
Delivery Method: Oral
Developer: South African Medical Research Council, University of Western Cape
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Alternative Name: ZK 98.299; ZK 98 299
User: Female
Hormonal: Yes
Developer: Schering AG
Development Stage: Pre-clinical

Pages

Displaying 21 - 30 of 52
Alternative Name: GyneFix 330
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shenyang Liren Medical & Technological Co.
Development Stage: Marketed
Alternative Name: Copper IUD for Nulliparous Women, Smaller Copper IUD T380
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Implementos Plasticos, Ltd., Mexico City
Development Stage: SRA/WHO PQ Approved
Alternative Name: SCu300 Intrauterine Devices, empira™
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: SRA/WHO PQ Approved
Alternative Name: LNG Contraceptive IUS (LCS); LCS16
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Bayer HealthCare
Development Stage: SRA/WHO PQ Approved
Alternative Name: Zarin; Femplant; Trust; Sino-implant (II)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Marketed
Alternative Name: Levosert (U.K.); Erlacela (Portugal); Donasert (Romania); Avibela
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Actavis, Medicines360
Development Stage: SRA/WHO PQ Approved
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: Regulatory
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Mona Lisa N.V.
Development Stage: SRA/WHO PQ Approved

Pages

CSV